255 related articles for article (PubMed ID: 22257383)
1. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
[TBL] [Abstract][Full Text] [Related]
2. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
3. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
4. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.
Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
J Hematother Stem Cell Res; 2002 Aug; 11(4):669-74. PubMed ID: 12201955
[TBL] [Abstract][Full Text] [Related]
6. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.
Li J; Chen QY; Mo H; Zhang YL; Huang ZF; Zeng YX
Int J Biol Sci; 2011; 7(5):607-17. PubMed ID: 21614153
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
[TBL] [Abstract][Full Text] [Related]
9. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
[TBL] [Abstract][Full Text] [Related]
10. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
11. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma.
Ferradini L; Miescher S; Stoeck M; Busson P; Barras C; Cerf-Bensussan N; Lipinski M; von Fliedner V; Tursz T
Int J Cancer; 1991 Feb; 47(3):362-70. PubMed ID: 1899651
[TBL] [Abstract][Full Text] [Related]
13. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy.
Li J; Zeng XH; Mo HY; Rolén U; Gao YF; Zhang XS; Chen QY; Zhang L; Zeng MS; Li MZ; Huang WL; Wang XN; Zeng YX; Masucci MG
PLoS One; 2007 Nov; 2(11):e1122. PubMed ID: 17987110
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma.
Ooft ML; van Ipenburg JA; Braunius WW; Zuur CI; Koljenović S; Willems SM
Oral Oncol; 2017 Aug; 71():16-25. PubMed ID: 28688685
[TBL] [Abstract][Full Text] [Related]
15. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Elsässer-Beile U; Grussenmeyer T; Gierschner D; Schmoll B; Schultze-Seemann W; Wetterauer U; Schulte Mönting J
Cancer Immunol Immunother; 1999 Jul; 48(4):204-8. PubMed ID: 10431690
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
17. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
18. EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias.
Xiao W; Li L; Zhou R; Xiao R; Wang Y; Ji X; Wu M; Wang L; Huang W; Zheng X; Tan X; Chen L; Xiong T; Xiong J; Jin Y; Tan J; He Y
Cell Mol Immunol; 2009 Oct; 6(5):367-79. PubMed ID: 19887050
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
Louis CU; Straathof K; Bollard CM; Gerken C; Huls MH; Gresik MV; Wu MF; Weiss HL; Gee AP; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
Blood; 2009 Mar; 113(11):2442-50. PubMed ID: 18971421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
